Table 3.
Statistical results of behavioral testing of ISO- and AIR-exposed mice.
| Variable | Comparison | Statistical test | Output | P value | Nonparametric |
|---|---|---|---|---|---|
| Total ambulations (across 10-min blocks) | Drug | two-way rmANOVA | F(1,31) = 2.497 | p = 0.124 | normal |
| Males only, Drug | rmANOVA | F(1,18) = 5.485 | p = 0.031 | normal | |
| Females only, Drug | rmANOVA | F(1,13) = 0.005 | p = 0.952 | normal | |
| Rearing (across 10-min blocks) | Drug | two-way rmANOVA | F(1,31) = 2.625 | p = 0.115 | normal |
| Males only, Drug | rmANOVA | F(1,18) = 0.447 | p = 0.512 | n/a | |
| Females only, Drug | rmANOVA | F(1,13) = 4.360 | p = 0.057 | normal | |
| Time at rest | Drug | two-way ANOVA | F(1,31) = 2.100 | p = 0.157 | normal |
| Male only, Drug | ANOVA | F(1,18) = 5.148 | p = 0.036 | normal | |
| Females only, Drug | ANOVA | F(1,13) = 0.017 | p = 0.898 | normal | |
| Time in center area | Drug | two-way ANOVA | F(1,31) = 0.049 | p = 0.823 | normal |
| Males only, Drug | ANOVA | F(1,18) = 0.162 | p = 0.692 | normal | |
| Females only, Drug | ANOVA | F(1,13) = 0.013 | p = 0.911 | normal | |
| Entries into center area | Drug | two-way ANOVA | F(1,31) = 1.343 | p = 0.255 | normal |
| Males only, Drug | ANOVA | F(1,18) = 4.072 | p = 0.059 | normal | |
| Females only, Drug | ANOVA | F(1,13) = 0.046 | p = 0.883 | U(15) = 21, p = 0.529 | |
| Accelerating rotarod (across 3 days/6 trials) | Drug × Day | two-way rmANOVA | F(1,62) = 3.153 | p = 0.049 | n/a |
| Day 2, Drug | multiple comparison | F(1,186) = 5.774 | p = 0.051 | U(35) = 89, p = 0.037 | |
| Day 3, Drug | multiple comparison | F(1,186) = 10.739 | p = 0.003 | U(35) = 92, p = 0.048 | |
| Males only, Drug × Day | rmANOVA | F(2,36) = 4.648 | p = 0.016 | normal | |
| Males only, Day 2, Drug | multiple comparison | F(1,108) = 1.602 | p = 0.208 | U(20) = 36, p = 0.315 | |
| Males only, Day 3, Drug | multiple comparison | F(1,108) = 8.594 | p = 0.012 | normal | |
| Females only, Drug × Day | rmANOVA | F(2,26) = 0.357 | p = 0.703 | normal | |
| Females only, Day 2, Drug | multiple comparison | F(1,78) = 3.946 | p = 0.050 | U(15) = 11, p = 0.066 | |
| Females only, Day 3, Drug | multiple comparison | F(1,78) = 3.307 | p = 0.073 | normal | |
| Time in open arm (across 3 days) | Drug | two-way rmANOVA | F(1,31) = 1.095 | p = 0.303 | n/a |
| Males only, Drug | rmANOVA | F(1,18) = 5.750 | p = 0.028 | n/a | |
| Females only, Drug | rmANOVA | F(1,13) = 0.007 | p = 0.934 | normal | |
| Percent time in open arm (across 3 days) | Drug | two-way rmANOVA | F(1,31) = 1.219 | p = 0.278 | n/a |
| Day × Sex | two-way rmANOVA | F(1.95,60.28) = 3.481 | p = 0.038 | n/a | |
| Males only, Drug | rmANOVA | F(1,18) = 5.425 | p = 0.032 | n/a | |
| Females only, Drug | rmANOVA | F(1,13) = 0.024 | p = 0.879 | normal | |
| Sociability, investigation zone time (social vs. empty) | Drug × Zone | two-way rmANOVA | F(1,31) = 0.010 | p = 0.920 | n/a |
| AIR, Zone | planned comparison | F(1,31) = 51.581 | p < 0.000005 | Z = −3.516, p = 0.0004 | |
| ISO, Zone | planned comparison | F(1,31) = 67.629 | p < 0.000005 | normal | |
| AIR males only, Zone | planned comparison | F(1,31) = 41.580 | p < 0.000005 | Z = −2.201, p = 0.028 | |
| AIR females only, Zone | planned comparison | F(1,31) = 16.726 | p = 0.0003 | normal | |
| ISO males only, Zone | planned comparison | F(1,31) = 38.926 | p = 0.000001 | normal | |
| ISO females only, Zone | planned comparison | F(1,31) = 29.340 | p = 0.000007 | normal | |
| Sociability, investigation zone entries (social vs. empty) | Drug × Zone | two-way rmANOVA | F(1,31) = 1.165 | p = 0.289 | normal |
| AIR, Zone | planned comparison | F(1,31) = 54.161 | p < 0.000005 | normal | |
| ISO, Zone | planned comparison | F(1,31) = 44.190 | p < 0.000005 | normal | |
| AIR males only, Zone | planned comparison | F(1,31) = 43.581 | p < 0.000005 | normal | |
| AIR females only, Zone | planned comparison | F(1,31) = 17.602 | p = 0.0002 | normal | |
| ISO males only, Zone | planned comparison | F(1,31) = 21.073 | p = 0.00007 | normal | |
| ISO females only, Zone | planned comparison | F(1,31) = 23.118 | p = 0.00004 | normal | |
| Social novelty, investigation zone time (familiar vs. novel) | Drug × Zone | two-way rmANOVA | F(1,31) = 2.882 | p = 0.099 | n/a |
| Sex × Zone | two-way rmANOVA | F(1,31) = 5.545 | p = 0.025 | normal | |
| AIR, Zone | planned comparison | F(1,31) = 19.266 | p = 0.0001 | normal | |
| ISO, Zone | planned comparison | F(1,31) = 5.662 | p = 0.024 | Z = −1.771, p = 0.077 | |
| AIR males only, Zone | planned comparison | F(1,31) = 23.975 | p = 0.00003 | normal | |
| AIR females only, Zone | planned comparison | F(1,31) = 3.095 | p = 0.088 | normal | |
| ISO males only, Zone | planned comparison | F(1,31) = 8.939 | p = 0.005 | Z = −1.988, p = 0.047 | |
| ISO females only, Zone | planned comparison | F(1,31) = 0.197 | p = 0.660 | normal | |
| Social novelty, investigation zone entries (familiar vs. novel) | Drug × Zone | two-way rmANOVA | F(1,31) = 2.457 | p = 0.127 | normal |
| Sex × Zone | two-way rmANOVA | F(1,31) = 5.462 | p = 0.026 | normal | |
| AIR, Zone | planned comparison | F(1,31) = 14.146 | p = 0.0007 | normal | |
| ISO, Zone | planned comparison | F(1,31) = 3.493 | p = 0.071 | normal | |
| AIR males only, Zone | planned comparison | F(1,31) = 25.172 | p = 0.00002 | normal | |
| AIR females only, Zone | planned comparison | F(1,31) = 0.759 | p = 0.390 | normal | |
| ISO males only, Zone | planned comparison | F(1,31) = 3.864 | p = 0.058 | normal | |
| ISO females only, Zone | planned comparison | F(1,31) = 0.506 | p = 0.482 | normal | |
| Males only, Novel Zone, Drug | multiple comparison | F(1,62) = 5.173 | p = 0.052 | normal |
For non-normal distributions, Mann-Whitney U and Wilcoxon Signed-Ranks nonparametric tests for two independent and paired samples, respectively, are also reported. Equivalent nonparametric test for two-way rmANOVA not available (n/a). Bonferroni correction reflected in p-values, where appropriate.